(NewsNation) — An experimental cancer vaccine has shown promising results in keeping pancreatic and colorectal cancers from coming back.
In a clinical trial led by the Jonsson Comprehensive Cancer Center at the University of California, Los Angeles, researchers tested the vaccine on 25 patients who had previously been treated for pancreatic and colorectal cancers.
Colorectal cancer is the third most common cancer diagnosed in both men and women in the United States, according to the American Cancer Society, and pancreatic cancer accounts for about 3% of all cancers in the country.
Researchers found that the vaccine, named ELI-002 2P, could trigger lasting immune responses and may help prevent or delay cancer recurrence in high-risk patients whose tumors are driven by KRAS mutations, whi